International Conference on
Sexually Transmitted Diseases, HIV/AIDS & Parasitic Infections

Dr. Maurice Y. Mongkuo is Professor of Public Administration at Fayetteville State University (FSU) and PI/Project Director of FSU MSI CBO HIV Prevention Project. Dr. Mongkuo has a BA degree from Kenyon College; and MPIA and Ph.D. in public policy research and analysis from the University of Pittsburgh. He has authored two books and over 30 peer-reviewed articles, monographs, technical reports, and policy briefings on HIV prevention behavior and socio-economic problems of at-risk minority youths and adults. He is currently the PI/Project Director of FSU Comprehensive Integrated Substance Abuse and HIV Prevention Program, and was a Co-PI of FSU Multi-level Integrated HIV Prevention Program. For over 20 years, Dr. Mongkuo has been the Principal Investigator, methodologist and Project Director of several government-funded policy research projects and community prevention projects involving at-risk minority populations and communities. He has also served as public policy consultant for several local and state governments and organizations where he assessed disparities policies and programs to enhance minority participation in government contracts and employment. He serves on the Editorial Board of 21 peer-review Medical and Public Health Journals. He has presented over 50 research papers and served as discussants at numerous professional conferences. Dr. Mongkuo has served as expert witness before governing boards on issues involving racial and ethnic minority representation in government contracting. Dr. Mongkuo also served as the Director of Development and Programs for the Pinellas County, Florida Urban League where he developed and sustained social and educational programs for at-risk persons in predominantly minority communities.

My research and scholarship portfolio is a diverse nexus of social science, and behavioral and public health research. I am the author of two books and over thirty refereed journal articles, monographs, and public policy research reports; and have serve as principal investigator/research director of numerous funded research and public service grant projects. My research and consultancy focus on at-risk health behavior, healthcare and economic disparities in underserved communities and people, global health, HIV/AIDS prevention behavior, evidence-based interventions and development , development and validation of measurement and structural models of at-risk behavioral health prevention, epidemiological methods, and public-private partnerships and collaboration. Throughout my career, I have conducted research and worked with university officials, and community stakeholders and constituents of underserved communities to develop effective community engagement and evidence-based intervention strategies. In recent years, my research has focused on developing global measurement and structural models for designing and assessing risky sexual behavior and health strategies for at-risk populations. I am the recipient of numerous awards, including a Certificate of Achievement for Outstanding Contribution and Commitment to the Advancement of Research and Sponsored Programs and Excellent in External Funded Grant Submissions awarded by Fayetteville State University Board of Trustees, and “Best Paper Award” for one of my published works on HIV prevention by the International Organization for Social Science and Behavioral Research (IOSSBR).

Wei Huang completed his PhD in Chemistry from University of Kentucky and postdoctoral studies from University of California, Davis. He is currently a staff research scientist at BD Biosciences at San Jose, California. He spent many years in the drug discovery industry and worked on antiretroviral drug development at Gilead Sciences, one of the leading pharmaceutical companies for HIV drugs. At BD Biosciences, he worked on the development of the FACSPrestoâ„¢ near-patient CD4 counter, which received CE-IVD and 510(k) clearance.

development of the FACSPrestoâ„¢ near-patient CD4 counter, which received CE-IVD and 510(k) clearance